Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Clinical Case Reports

Tatjana Zablocka¹  Sergejs Isajevs¹  Ineta Nemiro²  Eva Dručka³  Dana Kigitoviča³  Elizabete Pumpure⁴  Evija Olmane⁵  Raimundas Meškauskas⁶  Simona Doniņa⁷  Agnija Rasa⁸  Pēteris Alberts⁸ 

[1] Centre of Pathology Riga Eastern Clinical University Hospital Riga Latvia;Department of Diagnostic Radiology Oncology Centre of Latvia Riga Latvia;Department of Internal Diseases Riga Stradiņš University Riga Latvia;Department of Obstetrics and Gynaecology Riga Stradiņš University Riga Latvia;Department of Radiology Pauls Stradiņš Clinical University Hospital Riga Latvia;National Center of Pathology Affiliate of Vilnius University Hospital Santaros Klinikos Vilnius Lithuania;Oncology Centre of Latvia Riga East University Hospital Riga Latvia;R&D, Rigvir Riga Latvia;

关键词: ECHO‐7 virus;    melanoma;    oncology;    oncolytic virus;    Rigvir;    uterine cervix;   

DOI  :  10.1002/ccr3.2928

来源: DOAJ

【 摘 要 】

Abstract Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.

【 授权许可】

Unknown